Business Description
ESSA Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA29668H7085
Description
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.42 | |||||
9-Day RSI | 15.12 | |||||
14-Day RSI | 7.05 | |||||
3-1 Month Momentum % | -85.96 | |||||
6-1 Month Momentum % | -84.21 | |||||
12-1 Month Momentum % | -95.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EPIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ESSA Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.56 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.39 | ||
| 3-Year Sortino Ratio | -0.46 | ||
| Volatility % | 71.63 | ||
| 14-Day RSI | 7.05 | ||
| 14-Day ATR ($) | 0.043725 | ||
| 20-Day SMA ($) | 0.203155 | ||
| 12-1 Month Momentum % | -95.96 | ||
| 52-Week Range ($) | 0.18 - 6.45 | ||
| Shares Outstanding (Mil) | 47.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ESSA Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ESSA Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-08-13 | 0.20 (+0.60%) | ||
| Second quarter earnings results for 2026 | 2026-05-08 | 0.20 (+0.60%) | ||
| General meeting for 2025 | 2026-03-05 14:00 | 0.20 (+0.60%) | ||
| First quarter earnings results for 2026 | 2026-02-11 | 0.20 (+0.60%) | ||
| Annual report for 2025 | 2025-12-17 | 0.20 (+0.60%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-17 | 0.20 (+0.60%) | ||
| USD 1.690000 Cash Dividend | 2025-08-25 | 1.93 (+0.52%) | ||
| Third quarter earnings results for 2025 | 2025-08-13 | 1.91 (+0.53%) | ||
| Second quarter earnings results for 2025 | 2025-05-08 | 1.73 (+0.58%) | ||
| General meeting for 2024 | 2025-03-05 14:00 | 1.66 (+0.61%) |
Show
Entries
ESSA Pharma Inc Frequently Asked Questions
What is ESSA Pharma Inc(EPIX)'s stock price today?
The current price of EPIX is $0.20. The 52 week high of EPIX is $6.45 and 52 week low is $0.18.
When is next earnings date of ESSA Pharma Inc(EPIX)?
The next earnings date of ESSA Pharma Inc(EPIX) is 2026-12-17 Est..
Does ESSA Pharma Inc(EPIX) pay dividends? If so, how much?
ESSA Pharma Inc(EPIX) does not pay dividend.
Guru Commentaries on NAS:EPIX
Clark Street Value
Neutral
2025 Q2
What the manager wrote
ESSA Pharma (EPIX) is trading for $1.75/share and my estimate of its liquidation value is approximately $2.10/share. 9.5% shareholder BML and 5.1% shareholder Soleus Capital Management have both written public letters to the board pushing for a liquidation. Kevin Tang is also here with a 9.7% stake, but BVF Partners is the largest shareholder at 20%. In the Q1 results (filed after the Soleus & BML letters), EPIX included the line 'we have taken productive steps towards a decision and hope to share an update in the near future.' That was 53 days ago, hopefully a resolution will take place shortly.
Press Release
Articles on ESSA Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers